BURLINGTON, NC — (Business Newswire) — Labcorp^® (NYSE: LH), a leading global life sciences company, today announced a new collaboration with HealthVerity, the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data (RWD), that will expand Labcorp’s comprehensive, end-to-end drug development and clinical trial programs.

HealthVerity’s IPGE platform, an integrated technology and RWD infrastructure, enables Labcorp Drug Development and other participating companies to access fully interoperable, HIPAA-compliant data from the U.S.’s largest ecosystem¹ of health care and consumer data.

“This collaboration allows Labcorp to expand existing end-to-end solutions for drug and diagnostics development, commercialization and clinical trial efforts to include large-scale access to real-world data for research applications,” said Dr. Paul Kirchgraber, CEO of Labcorp Drug Development. “By applying advanced analytics, Labcorp can help its clients improve their processes and reach better outcomes. Our substantial repository of test results can also help study sponsors more quickly and accurately assess patient eligibility for clinical trials, enroll patients faster and accelerate the availability of new medicines.”

Now more than ever, study sponsors are seeing the potential of RWD to yield longitudinal patient insights before, during and after trials. With more predictive analytics and artificial intelligence applications requiring comprehensive and fully interoperable RWD, Labcorp can align de-identified patient data with ten times greater accuracy² than industry alternatives by using the HealthVerity IPGE platform. In addition, access to HealthVerity’s RWD with on-demand de-identification and data linkage capabilities reinforces Labcorp’s ability to be a trusted source of information for its clients.

“Fragmentation of patient data is at an all-time high, and the goal is no longer just connecting this data,” said Andrew Kress, CEO of HealthVerity. “Rather, the goal is making data more accessible and useful for gaining a detailed understanding of patient journeys. With analytics and applications requiring more frictionless access to the data itself, the HealthVerity IPGE platform stands alone in offering the ability to combine transaction-level patient data in a de-identified, fully interoperable manner, and delivering it directly into the client’s applications of choice.”

Labcorp is an investor in HealthVerity through the Labcorp Venture Fund.

View the full release here: https://www.businesswire.com/news/home/20220620005641/en/

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com

¹ Internal data from HealthVerity

² Internal data from HealthVerity

Labcorp Contacts

Media: Christopher Allman-Bradshaw — 336-436-8263
Media@Labcorp.com

Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com

HealthVerity Media Contact

Jennifer Kaczmarczyk
Vice President, Marketing
jkaczmarczyk@healthverity.com

ALEXANDRIA, VA — (ASCO) — CancerLinQ^® LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology, and HealthVerity, Inc., today announced a collaboration that will create the nation’s premier real-world oncology data ecosystem to advance cancer care and research for government and public health agencies. The collaboration leverages HealthVerity’s Privacy-Preserving Record Linkage (PPRL) technology to make CancerLinQ oncology data fully interoperable with de-identified patient data from the nation’s largest ecosystem of healthcare and consumer data providers. Qualified researchers will now have the ability to explore longitudinal patient journeys across a multitude of data types that better reveal the context around the origin, progression, treatment, and outcomes for a full breadth of cancer diagnoses.

With only 5 percent of patients with cancer participating in clinical trials, the use of real-world oncology data in research can help expand the pool of knowledge from which researchers can learn. CancerLinQ and HealthVerity allow researchers to learn from all patients with cancer – not only those enrolled in clinical trials–by providing access to broadscale, patient-longitudinal, real-world data that can provide researchers with a more comprehensive view of unique patient journeys.

“CancerLinQ is driven by its goal of improving the care of every single patient with cancer,” said Sean Khozin, MD, MPH, chief executive officer (CEO) of CancerLinQ. “To that end, this new collaboration helps us bring together disparate data-sets that capture the longitudinal experience of patients with cancer, giving us the ability to unlock insights that inform high-quality, equitable patient care and research.”

“We are thrilled to be working alongside CancerLinQ to offer researchers a more comprehensive way to study the complex journeys of cancer patients,” said Andrew Kress, CEO of HealthVerity. “By leveraging the HealthVerity IPGE platform to connect real-world datasets in a HIPAA-compliant and privacy protected manner, we are creating an incredible opportunity for public health and government agencies to make the discoveries that could one day lead to cures for most forms of cancer.”

CancerLinQ has one of the largest and most-diverse real-world-oncology databases that include de-identified data from more than six million patients with cancer and benign hematological conditions from all 50 states. The CancerLinQ network is a growing ecosystem of over 100 cancer centers and community oncology practices.

The HealthVerity IPGE platform is an integrated technology and real-world data infrastructure platform based on four foundational elements—identity, privacy, governance, and exchange—which allow disparate data to be accurately resolved to unique privacy-protected identities, linked, and exchanged for a myriad of use cases.

To learn more about the collaboration and how you can access one of the nation’s largest interoperable de-identified real-world oncology data ecosystem, visit CancerLinQ.org.

View the full release here: https://www.asco.org/about-asco/press-center/news-releases/cancerlinq-and-healthverity-collaborate-linking-datasets

About ASCO

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer’s full continuum. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, Instagram, and YouTube.

About CancerLinQ

CancerLinQ^® is a real-world oncology data platform developed by ASCO that collects and aggregates longitudinal EHR data from oncology practices throughout the United States. CancerLinQ improves the quality of patient care and accelerates discovery by securely compiling, harmonizing, analyzing, and de-identifying vast amounts of information on patient characteristics (e.g., molecular profiles, comorbidities), treatments, and long-term side effects. By using data from over six million patients in near real time, CancerLinQ can identify trends and associations between myriad variables, thereby enabling physicians to generate new hypotheses and apply those conclusions to improve care in real-world settings. To learn more about collaborations, visit Collaborations | ASCO CancerLinQ.

About HealthVerity

Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com.